Podcasts about Biomedicine

ReferencesScience. 2013 Nov 8;342(6159):727–730.Biomedicine & Pharmacotherapy 2025. Volume 183, February Guerra, DJ.2026. Unpublished LecturesBeethoven, LV. 1812. Symphony 8 in F Major. Op93https://music.youtube.com/watch?v=FMEL6z9Qir8&si=ycnEA9nSZrLqkKca

References Cell Death & Disease 2018. v. 9, Article number: 600CNS Neuroscience & Therapeutics 2009. 15:32–51Oncol Lett 2016 Aug;12(2):897-903.Cell Death Discovery  2025V 11, Article number: 489 Biomedicine & Pharmacotherapy2024 v. 172, March 116229Guerra, DJ. 2026. Unpublished Lectures.Lennon/McCartney.1968. I'm So Tired. White Album-Beatleshttps://open.spotify.com/track/2X9H5BokS1u5O46YpNYNsZ?si=bdcc11350bc24d90Dubin/Warren. 1935.Lullaby of Broadway -Doris Day.(1951).https://open.spotify.com/track/4hG3Xgm6H4ELBi8ESQoosr?si=b5a84bdc0be84dbc

Guest: Dr. Samuel Nobs is an Assistant Professor and Group Leader at the Institute for Research in Biomedicine in Switzerland. He discusses how microbes in the lungs and gut may shape respiratory immunity and influence susceptibility to infections and chronic lung diseases. He highlights his lab's work to uncover the mechanisms behind these interactions using microbiome analysis and advanced experimental models. Featured Products and Resources: Download a practical guide on everything you need to know about cell isolation techniques. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Rabbit Immunity Evolves – Wild rabbits rapidly evolved resistance to myxoma virus through changes in highly diverse MHC immune genes. Antifungal Receptors Improve Vaccines – Targeting antifungal immune receptors with a mannan-based adjuvant boosts the strength, durability, and variant coverage of mRNA vaccine responses. Mapping Tumor Macrophage Diversity – Scientists have revealed how diverse tumor-associated macrophage subtypes promote tumor growth, immune suppression, and metastasis through interactions within the tumor microenvironment. Dietary Soy Shapes Immunity – Dietary soy shapes the gut microbiome to boost IgA-mediated immunity and enhance protection against intestinal infection in early life. Image courtesy of Dr. Samuel Nobs. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Humanity is actively working towards a mission to Mars. When astronauts like Bernard Harris leave Earth, they accept risk as part of the mission. But a journey to Mars would push that risk into entirely new territory—where help is unreachable, uncertainty is unavoidable, and coming home may not be an option. This episode explores how space agencies, astronauts, and all of us need to grapple with how much risk is ethically acceptable for individuals to take on in pursuit of societal benefit, and who gets to decide. This episode features:Bernard A. Harris Jr., MD: former NASA astronaut.James D. Polk, DO: Chief Health and Medical Officer of NASA.Jeffrey Kahn, PhD, MPH: Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics.“playing god?” is a podcast by the iDeas Lab at the Johns Hopkins Berman Institute of Bioethics. To read a transcript of this episode, visit the iDeas Lab website at https://bioethics.jhu.edu/pgs2e2.The Johns Hopkins University Sesquicentennial is proud to support this podcast. JHU celebrates 150 years of pioneering education and research—advancing knowledge to meet the challenges of every generation. Learn more at 150.jhu.edu.

When journalist Esmé Deprez receives a text from her father, Ron Deprez, asking for help to die, she enters one of the most ethically fraught spaces in modern medicine: Medical Aid in Dying (MAiD). This episode explores what it means to assist a loved one's death under MAiD law—and how personal compassion collides with professional and societal ethics.This episode features:Esmé E. Deprez: Writer and investigative journalist. Jeffrey Kahn, PhD, MPH: Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics.Jennifer Eitingon, MD: Medical Director of Monument Health Hospice and Inpatient Palliative Care Attending Physician.You can see photos and read more about Esmé and Ron Deprez's story in her 2021 essay, “Death With Dignity: How I Helped My Dad Die.” “playing god?” is a podcast by the iDeas Lab at the Johns Hopkins Berman Institute of Bioethics. To read a transcript of this episode, visit the iDeas Lab website at https://bioethics.jhu.edu/pgs2e1 The Johns Hopkins University Sesquicentennial is proud to support this podcast. JHU celebrates 150 years of pioneering education and research—advancing knowledge to meet the challenges of every generation. Learn more at 150.jhu.edu.

Life and death decisions. Difficult tradeoffs. “playing god?” explores ethical dilemmas in health and medicine through the first-person stories of people who have lived them. Brought to you by the Dracopoulos-Bloomberg iDeas Lab at the Johns Hopkins Berman Institute of Bioethics. New episodes weekly starting May 19. 

On this month's episode of the WHOOP Podcast Longevity series, WHOOP SVP of Research, Algorithms, and Data Emily Capodilupo sits down with Google Deepmind AI Researcher Vivek Natarajan to explore how large language models are transforming healthcare and biomedical research. Emily and Vivek discuss AI's potential to both accelerate scientific discovery, such as developing new treatments and understanding diseases, and expand access to care globally by delivering medical guidance more equitably. The episode examines how AI can augment, rather than replace, doctors by improving diagnostics, increasing efficiency, and enabling more personalized care, while highlighting the importance of trust, safety, and human connection as these technologies evolve. (00:47) Understanding The Intersection of Large Language Models and Biomedicine(02:26) How To Approach AI in the Healthcare Landscape(05:52) What Is The Role of the Doctor as AI Becomes More Popular(09:39) What Does The Future of AI Healthcare Look Like? (12:51) Clinical Care: Where Can AI Assist?(16:03) Exploring The Dangers of AI (18:43) Process of Teaching Physicians and Users To Use AI (22:22) What Are The Areas of Concern Over AI?(24:12) Regulation and Pace of Development(26:51) Gaining and Maintaining Trust While Building AI Algorithms(30:38) The Impact of AI on Research(37:44) Biggest Misconception Regarding AI in HealthcareFollow Vivek Natarajan:LinkedInSupport the showFollow WHOOP:Sign up for WHOOP Advanced LabsTrial WHOOP for Freewww.whoop.comInstagramTikTokYouTubeXFacebookLinkedInFollow Will Ahmed:InstagramXLinkedInFollow Kristen Holmes:InstagramLinkedInFollow Emily Capodilupo:LinkedIn 

Although rare, recognizing NMOSD is crucial for improving patient outcomes through correct diagnostic and treatment approaches. Reports of atypical forms and increasing knowledge of clinical, imaging, and laboratory-specific features are fundamental for the accurate recognition of this condition. Research on targeted therapies and biomarkers measuring and predicting disease activity will improve NMOSD management. In this episode, Gordon Smith, MD, FAAN, speaks with Sara Mariotto, MD, PhD, coauthor of the article "Neuromyelitis Optica Spectrum Disorder" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Mariotto is a neurologist in the Neurology Unit in the Department of Neurosciences, Biomedicine, and Movement Sciences at the University of Verona in Verona, Italy. Additional Resources Read the article: Neuromyelitis Optica Spectrum Disorder Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @GordonSmithMD Full episode transcript available here Dr Smith: Neurology is an increasingly therapeutic specialty, and across many of our subspecialty areas, lots of new drugs are being approved. Are you interested in learning more about a historically disabling disorder for which we now have a spectrum of new therapies that, if used appropriately and promptly in the right clinical situation, promise to dramatically improve patient outcomes? If so, keep listening. My name's Dr Gordon Smith. Today I'll be talking with Dr Sara Mariotto about her article on neuromyelitis optica spectrum disorder or NMOSD, which she wrote with Dr Romain Marignier. This article appears in the April 2026 Continuum issue on multiple sclerosis.  Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Smith: This is Dr Gordon Smith. Today, I'm interviewing Dr Sara Mariotto about her article on neuromyelitis optica spectrum disorder or NMOSD, which she wrote with Dr Romain Marignier. This article appears in the April 2026 Continuum issue on multiple sclerosis. Sara, welcome to the podcast, and maybe you can start by introducing yourself to our audience.  Dr Mariotto: Yes. Thanks, Gordon. I'm Sara Mariotto. I'm a neurologist, and I work at the Neurology Unit, University of Verona, where I do both clinical diagnosis and research into neuroimmunology---so, in particular, autoimmune encephalitis, NMOSD, and MOGAD.  Dr Smith: Well, this is a super exciting area. Whenever I hear about NMOSD, I think of one specific patient I had, and I always think of her when I come across something like your article, which is really fantastic. So, before we dive into the details, I wonder if maybe you can just explain to our listeners who aren't up to speed on what NMOSD is, what the disorder is, and maybe why it's so important that all of our listeners learn how to recognize it quickly and get people started on therapy.  Dr Mariotto: Yes, sure. So, neuromyelitis optica is an inflammatory autoimmune CNS disorder usually associated with aquaporin-4 antibodies, although there are a few cases, around 10%, who can be antibody-negative. And I think it's very much important to have in mind this disease and recognize it because it can be severe, as you pointed out; can present with very severe optic neuritis, myelitis, the brain stem, or area postrema syndrome. So, it can be really severe, affect quite young people around 40 years of age---although it can affect also the pediatric population and elderly people---and, importantly, it can be treated. It's very much important to treat this patient in the acute stage very quickly with steroids or plasma exchange in addition, and then to start a chronic treatment. So, we have treatment for this condition. So, it's very much important to, to recognize it quickly and treat the patient properly.  Dr Smith: So, I wonder if we can talk a little bit about the diagnostic criteria and boundaries of NMOSD, right? So, someone who comes in with bilateral op- severe long segment optic neuritis or long segment myelitis, we think about it. But what are the boundaries? Should we be looking for this, for instance, in someone who comes in with a unilateral optic neuritis or looks like typical multiple sclerosis? Is it important to get aquaporin-4 antibodies in those patients? What do the diagnostic criteria say about this?  Dr Mariotto: So, I wouldn't test aquaporin-4 antibodies in all patients with demyelinating conditions because although aquaporin-4 antibody assay is very specific, as for all assay and all antibody testing---also for MOG antibodies, for example---some false positive results can come out. So, I would suggest to test aquaporin-4 antibodies not in typical MS cases but in those who could be suggestive for not being MS, so in all those cases with atypical optic neuritis and myelitis or other syndromes. For those cases, it's important to test aquaporin-4 antibodies, but I wouldn't test them in all typical, classical MS cases. As I said, it's quite specific, the assay, so it's uncommon to have false positive results, but it can be.  Dr Smith: Serum, CSF, both?  Dr Mariotto: So, for aquaporin-4 antibodies, they're usually present in serum. They can be positive also in the CSF. And there are a few reports of isolated CSF positivity. But if we analyze larger samples volume, then it becomes clear that isolated CSF positivity is so, so rare that it's not recommended to test them in the CSF when serum is negative. So, for aquaporin-4 antibodies, the recommended matrix of testing is serum, which is different for MOG, which is not the topic of our article but is important to mention because MOG antibodies should be tested in serum and CSF. But aquaporin-4, I would recommend to test serum.  Dr Smith: What are the boundaries between MOGAD and NMOSD? And you talked about the differential testing of antibodies, which I was going to ask about. But when should we think of NMOSD relative to MOG? Dr Mariotto: Yeah. There are aspects which are the one mentioned in the criteria, highly suggestive for NMOSD. But the clinical spectrum can be similar to that of MOGAD. Usually, although there are some clinical aspect---like, for example cortical encephalitis or ADEM, which is more typical for MOGAD, or others like area postrema syndrome, which are more typical of NMOSD. The spectrum can be similar among the two conditions, so that's why in our clinical experience, usually they ask both aquaporin-4 and MOG antibodies in patients. It's- for experts, it can be easy to differentiate the two conditions, but for nonexperts can not be so easy.  Dr Smith: Can you define area postrema syndrome? I think not all of our listeners see that every day.  Dr Mariotto: Yeah, sure. This is a syndrome which is highly suggestive of NMOSD. That's why I mention it. And it's characterized by nausea, vomiting, hiccups are known as the syndrome. And it is very, very suggestive because of the expression of aquaporin-4 in that area of NMOSD. That's why I strongly recommend for all patients who comes out to have this syndrome to test for aquaporin-4 antibodies. MOGAD is hardly ever positive for that, so I think that whenever you see a patient with that syndrome, you should think about NMOSD.  Dr Smith: I'm just curious, aquaporin-4 is a water channel, which is kind of an interesting concept. Our conversation, I really want to make sure we give clinically important information to folks, but it's so curious to me at least, how does this actually result in a inflammatory demyelinating syndrome? For a simple neuromuscular guy, what's the immunopathogenesis of this?  Dr Mariotto: Yeah, the immunopathogenesis is quite complicated, as in all CNS disorders. And of course, aquaporin-4 antibodies are the main focus, but they are not the only one. As you said, aquaporin-4 antibodies have a target, this water channel, which is at the basis of the disease, and they are produced by the interplay between T cells, B cells, and plasma cells. But then also eosinophils, macrophages, cytokines, and chemokines are involved, enter the CNS, and then another important component is complement, which is highly activated in this disease. At the end, we have astrocyte damage because astrocytes are the main target of the disease, but also axon and myelin are involved. So, it's a quite complex pathogenesis based on the antibodies, but not only on that.  Dr Smith: And this will become important when we start talking about treatment. There seems to be a recurring theme of long segment demyelination, right? Optic neuritis is typically a large percentage of the length of the optic nerve, and obviously the myelitis se- more than three segments. Do you see other long segment areas of CNS demyelination, corpus callosum or things like that? Any ideas why that is, if that's true?  Dr Mariotto: Of note, this is quite interesting because usually when we have NMOSD, we have a longitudinal involvement, especially of the optic nerve and spinal cord, while brain lesions are quite different. Like, we usually do not have the typical Dawsen fingers-like lesions that we have in MS, for example, or the classical periventricular or subcortical extensive lesions that we can see and we have in mind when we think about MS. In some cases with NMOSD, the brain is completely negative, so we do not see anything. And Dawsen lesion's quite suggestive of NMOSD. So, you're right. I mean, this is related partially to the expression of aquaporin-4, and that's why we have this typical involvement also for area postrema, for example, and maybe also our other examples of clinical aspect that we can see in these conditions. But it's basically linked with the expression of aquaporin-4, which is the main target of the disease. And that's why usually the brain doesn't show so much involvement as we can see in MS, for example.  Dr Smith: I was actually really interested in some of the unusual manifestations or phenotypes, and I don't want to get into arcadia, really, but which of these should our listeners be familiar with that would really suggest that they should be thinking about NMOSD beyond the area postrema and other features that we've already talked about that are part of the core criteria?  Dr Mariotto: Yeah. I mean, I think that the encephalic syndromes or also ADEM, which is most typical of MOGAD but can be observed also in NMOSD or PRES, for example, are syndromes that can be considered in patients with NMOSD. There are the typical ones, which are the ones showed in the criteria, but whenever we have a brainstem involvement or, like, these encephalic syndromes or also PRES, we should think about NMOSD also.  Dr Smith: Another area I was interested in are red flags. In your article, you talk about red flags that might suggest an alternative diagnosis, right? And then this presumably is particularly important in seronegative patients, which 10% is not a reasonably high number, I suppose. What are red flags we should be thinking about for some other diagnosis?  Dr Mariotto: Yeah. I would here mention two very important red flags. The first one is a very hyperacute onset. Usually these conditions, these inflammatory conditions have a subacute onset, so whenever you have a very, very acute onset, you should think about something else. This can occur sometimes also in NMOSD, but hardly ever occur. Like, a very acute myelitis, the first thing we should think about is a vascular origin, for example, with a lot of pain and not about NMOSD, although sometimes the differential diagnosis is not so easy. The second thing is a progression independently of relapses, which hardly ever occur in NMOSD. Usually in NMOSD, we have the onset, and then we have a relapsing disease course. That's why we have to treat patients always and not to stop treatment. But we do not have progression in the meanwhile, while we can have, for example, this in MS. Same thing is for MOGAD. So, these are two things that I think is very much important to keep in mind.  Dr Smith: I want to pivot to talk about treatment because that's been super exciting. But rumor has it there are new diagnostic criteria coming for NMOSD in the next year. I bet you know a bit about those. Can you give our listeners any indication about kind of where the puck is going on this? Not so much what the criteria are specifically, but what sort of diagnostic challenges are the new criteria going to help us with once they come out?  Dr Mariotto: Yeah. So basically, we are working on that, so you will read them in the next future. This is the good point of the conversation on the new criteria. And we work a lot on the definition, on the new definition and nomenclature of NMOSD; on the definition of seronegative NMOSD, which is also quite tricky; and then on the assay we should use to test aquaporin-4 antibodies, and also on potentially new syndromes which should be included into the main feature of the disease. But hopefully you will read about this very soon.  Dr Smith: Looking forward to it. And Continuum Audio listeners, you heard it here first, so thank you. Let's pivot to treatment. This has been super exciting, and I wonder if the way to approach this is to start with acute management and then sort of chronic management. Would that make sense?  Dr Mariotto: Sure.  Dr Smith: Let's say I go on service on Friday, and I have a patient who comes in with positive aquaporin-4 and bilateral optic neuritis. What's the acute approach to managing that patient?  Dr Mariotto: So, the first approach is to administer intravenous steroids, but I would not wait to escalate to plasma exchange. There is quite good evidence that we should treat the patient with additional plasma exchange very quickly, and every day of delay of plasma exchange can cause increased disability. So, we should treat patients with steroids first, and then if we are not satisfied by the recovery, soon start with a plasma exchange. There is also some evidence, although less, for IVIG, but it's important to try to treat them very quickly, even if it's Friday, you know, there is the weekend and so on. But I think it's very much important to start with steroids after excluding other infectious causes or so on, and then to start quickly with plasma exchange. The main problem could be that we do not have the results of the antibody yet.  Dr Smith: Right. So, let me ask that question. You know, let's say my patient comes in on Friday, and clinical syndrome that really looks like NMOSD, and we're waiting for the aquaporin-4. There are many places where it's hard to get plasma exchange over weekends. And so, in that setting, are you better off doing the steroids over the weekend then PLEX on Monday, or should we just give IVIG because maybe it's as good as PLEX? What's your advice there? I'm trying to get ready for Friday because I know one's coming in.  Dr Mariotto: That's true, that's true. Usually they come on Friday or Saturday. I think it's acceptable to have three days of steroids and see how the patient improves, and then after three days to start with plasma exchange. Actually, we have a very good improvement if we start between three and five days after onset. So, I think waiting for three days is acceptable just because we can see if the steroids work properly or not, and then we can quickly start to plasma exchange. But I would not wait, like, 10 days, you know, before starting with a plasma exchange, and I would not wait for antibody results.  Dr Smith: Got it. Super helpful. And I'm actually not joking around, I learned recently that I have a reputation among our residents for having lots of optic neuritis when I'm on service, which I think is sort of karmic justice for being a peripheral nerve expert. But let me ask another question. So, let's say we do that, and the patient gets three or five days of pulse methylprednisolone and five courses of PLEX, and they're not doing well. Do you then just move right along into another agent B cell depletion therapy? I mean, what's your next step in escalation in the acute setting?  Dr Mariotto: I would for sure start to, as you said, with steroids, plasma exchange, and in case IVIG, and then quickly move to chronic treatment. And for patients who are not recovering well, I would think of something which has a quick effect so we can really start treating patients very quickly. There are different options. And all over the world, there are different rules for using immunosuppression in NMOSD. Like in Italy, for example, it's different from US or other countries, Germany, for example. There are different approved treatments and different rules of using them before or after rituximab, for example. We all know that there are treatments approved for NMOSD all over the world. But in some countries, like for example in Italy, we should use rituximab first, and then if it doesn't work, escalate to the approved treatment. I know in the US it's different. But anyway, for a patient who does not improve quickly, I would start with something which has a quick effect on the disease.  Dr Smith: And then rituximab versus inebilizumab, you know, CD20, CD19, what's your advice there? Is one preferable to the other, you know, if we have options to do either?  Dr Mariotto: Yeah. So, between rituximab and inebilizumab, we know that the target, well, is different, but is anyway B cells, so CD19 and CD20. With CD19, we can affect both plasma blast, plasma cells, and B cells. That's why the target is broader. And of note, this is an approved drug, while rituximab is, in most countries, used as off-label treatment.  Dr Smith: So inebilizumab would probably be preferable if we're able to do that.  Dr Mariotto: Unfortunately, there are not so many studies comparing rituximab with the approved drug, which is, of course, a pity, but that's the case. While we have clinical trials for all the approved drugs, and although the trials were designed differently, as we mentioned in the Continuum paper, we can argue something of the comparison between the approved drugs. But it is not so clear the comparison between rituximab and the new drugs, which is also something that we should work on.  Dr Smith: And then for chronic suppressive management, what other options are there?  Dr Mariotto: So, in addition to B cells, target can be interleukin-6, as we know with tocilizumab or satralizumab, and then complement with eculizumab. These drugs are both based on the pathogenesis of the disease. That's why we also discuss it in the paper, which shows a clear involvement of complement, and among cytokines of interleukin-6. So, targeting these made clear that could improve the disease quite well, and that's why they designed some clinical trials on these drugs, which are now approved, as we said, for NMOSD.  Dr Smith: Wow, so many options, and a lot of questions, but limited time. Let me just ask a couple of more. I see a lot of myasthenia patients, and there's a lot of variability, as you know, in patients with myasthenia, the extent to which complement is an important mechanism versus other, you know, important mechanisms. To what extent is response to a complement inhibitor kind of uniform across NMOSD? Or there's some patients who just don't respond to a complement inhibitor and others that respond really well. And then just, I'll just give my second question out is, you know, what about combination therapies for patients who have particularly challenging NMOSD?  Dr Mariotto: So usually these patients have a terrific response to complement inhibitors, and this is also shown by the clinical trials where we saw how eculizumab have a very impressive effect on the disease. And also, maybe this is also your experience, a very quick effect. So that's why there are also thoughts on using it in a very acute stage of the disease. That was what I was thinking about before. But then it has a very huge effect on complement, which is a major factor involved in the pathogenesis of NMOSD also in the chronic disease stage, and that's what also we see from clinical trials. Usually, we prefer to switch treatment from one to another and not to combine them. Of course, in very difficult cases, this can be considered, but the recommendation is to switch from one of these approved drugs to the other, or from rituximab to one of the approved drugs, and try to find out the best for our patient before combining them. Dr Smith: The complement inhibitor trials are breathtaking, at least for me. If I'm trying to convince students to go into neurology, I'll say, "Take a look at that paper," because anyone who claims that we're "diagnose and adios" is so wrong. It's so exciting. So, at a high level, this must have fundamentally changed outcomes for patients. I mean, it's still a difficult disease, but what is the kind of prognosis for that patient I described who comes in, gets the therapy you talked about? What does their long-term outcome look like in this modern therapeutic environment? Dr Mariotto: So, NMOSD is almost always a relapsing disease. That's why, as we mentioned, we have to treat patients always. But the prognosis changes a lot since we were also able to use all these drugs for the disease. So, the prognosis changes if we recognize it properly and early, and if we treat NMOSD properly with immunosuppressives. So, whatever we choose it's important to start it quickly, and this is the only way that we have to improve the prognosis of this disease. We have very active cases, but we have also cases who responds quite well to this immunosuppressive treatment, since now we have, as mentioned, these ones which are very impressive and show incredible results. So, the prognosis of the disease change in the last year, thanks also to the improvement of the diagnosis and of the treatment choices for the disease.  Dr Smith: I'm just... I- maybe my last question, you know, just at a personal level, not only for you as an expert who's caring for these patients, but in the patient community, this must have been a pretty exciting period of time, right? I mean, these, these drugs are coming fast and furious, and what a change. What's the kind of zeitgeist in the community, both your professional community and amongst the patient community about where we are? Dr Mariotto: Yeah, you're right. The last years were defined the years of NMOSD and also MOGAD because we had finally approved drugs which is relevant for all the disease that we treat and changed the landscape of the disease for clinicians, but also for patients. And we have more than one, as we said, so we have more options that we can also discuss with patients to try to choose the best one in terms of activity, but also route of administration or time. Some years ago, we just had rituximab, which is not approved in most of the countries, and now we have different approved drugs. And we improved the diagnosis of the disease thanks to the availability of live cell-based assay. And then we are working a lot also on biomarkers like GFAP, for example, which has been shown to be a very attractive biomarker able to mark disease activity and maybe also prognosis on this disease. So, you're right. I mean, in the last years, the landscape of NMOSD changed a lot.  Dr Smith: Sara, thank you so much for talking with me. I could keep going for another half an hour, but I would be in trouble with my editor, so I think we probably need to wrap it up. But thank you so much. This has been very informative.  Dr Mariotto: My pleasure. Dr Smith: Mine too. Thank you. Again, today I've been interviewing Dr Sara Mariotto about her article on NMOSD, which she wrote with Dr Romain Marignier. This article appears in the April 2026 issue of Continuum on multiple sclerosis. Be sure to check out Continuum Audio episodes from this and other issues, and thanks to you, our listeners, for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Happy trans day of audibility! Headlines: CW: Aboriginal and Torres Strait Islander peoples should note that this headline mentions the name of a deceased person.The coronial inquest into the passing of proud Noongar man, Jeffrey Winmar began yesterday on Monday 30th of March.Iran's parliament speaker has accused the United States of plotting a ground attack despite publicly pushing for a negotiated deal, as the US deploys thousands of military personnel to the region.  Iran's parliament speaker has accused the United States of plotting a ground attack despite publicly pushing for a negotiated deal, as the US deploys thousands of military personnel to the region.  Australia's states are split over free public transport as the war in the Middle East drives fuel costs higher, with Victoria and Tasmania waiving fares while NSW, Western Australia, Queensland and South Australia have ruled out following suit.  Israeli police have prevented Cardinal Pierbattista Pizzaballa, the Latin patriarch of Jerusalem, from entering the Church of the Holy Sepulchre to mark Palm Sunday Mass.  7:15am // Rory from Vixen spoke at Saturday's Trans Day of Vengeance, which took place outside the State Library of Victoria. Some of the key demands from individuals and groups organising this event were: accessible gender affirming care for all, cops and zionists out of Pride and no Pride in detention. You can follow Vixen on Instagram at @vixenworkers or go to vixen.org.au  7:30am // Lushy Chingaya is the current University of Melbourne Student Union President, Hansen Scholar and Biomedicine student. She is a dedicated advocate for students on campus, with a focus on advocating for equity, representation, and community wellbeing. Lushy is on the program to discuss demands calling for the University of Melbourne to scrap its indoor protest ban.  7:45am // Nazanin is an Iranian feminist speaking out against injustice within Iran here for part two of an interview conducted two weeks ago. Nazanin is part of a feminist group here in Naarm called Feminista Melbourne https://www.instagram.com/feminista.melbourne/, a group of artists and activists fighting for freedom of Iran. Just a pre-warning for listeners, some of this content may contain discussion around sexual abuse and violence, please take care while listening.  8:00am // Jing Xuan Teo runs Amplify Bookstore, which specialises in stocking books by BIPOC authors, based here in Naarm. Amplify aims to help readers diversify their bookshelves and to tackle issues of representation in the publishing industry. Xuan is here to discuss what Amplify has been up to in the past year, their expanding events calendar, and book recommendations. You can find out more at amplifybookstore.com or @amplifybookstore on Instagram. 8:15am // In this speech also from the Trans Day of Vengeance, Slumbi connects liberation and justice for trans people to other struggles in the world, including the fight against colonialism and white supremacy. She also speaks to the importance of organising by and for the community and ends her speech by calling on everyone to imagine and organise community-run gender affirming care. Songs: Everything U Are by Nada Keroncong - Keroncong is a unique classical colonial Indonesian musical genre that first developed in Java Island, especially at the port cities of Sunda Kelapa. The original song, Everything U Are was written and performed by Indonesian singer songwriter Hindia. Azaa by Omnia T Al Taher -  Omnia Al Taher, teamed up with Mory and Sudanese group Rap Shar3 to create this blues-rock, politically charged “Azaa"

Join us as Declan and Roger discuss the evidence for routine table tilt during elective caesarean section.   Has this changed your practice? What is your opinion on this topic? We'd love to read your emails.  As mentioned in the episode we would love to do a future episode on Q&A so if you have any questions on any topic you would like us to tackle please send them in! Send your comments / questions to: obsgynaecritcare@gmail.com References Hughes EJ, Price AN, McCabe L, Hiscocks S, Waite L, Green E, Hutter J, Pegoretti K, Cordero‐Grande L, Edwards AD, Hajnal JV. The effect of maternal position on venous return for pregnant women during MRI. NMR in Biomedicine. 2021 Apr;34(4):e4475.  Couper S, Clark A, Thompson JM, Flouri D, Aughwane R, David AL, Melbourne A, Mirjalili A, Stone PR. The effects of maternal position, in late gestation pregnancy, on placental blood flow and oxygenation: an MRI study. The Journal of physiology. 2021 Mar;599(6):1901-15.  Higuchi H, Takagi S, Zhang K, Furui I, Ozaki M. Effect of lateral tilt angle on the volume of the abdominal aorta and inferior vena cava in pregnant and nonpregnant women determined by magnetic resonance imaging. Anesthesiology. 2015;122(2):286-293.  Fujita N, Higuchi H, Sakuma S, Takagi S, Latif MA, Ozaki M. Effect of right-lateral versus left-lateral tilt position on compression of the inferior vena cava in pregnant women determined by magnetic resonance imaging. Anesthesia & Analgesia. 2019 Jun 1;128(6):1217-22.  Aust H, Koehler S, Kuehnert M, Werdehausen R, Schleppers A, Reese PC, Reyher C. Guideline-recommended 15° left lateral table tilt during cesarean section in regional anesthesia—practical aspects: an observational study. Int J Obstet Anesth. 2016 Aug;27:47-53.  Crawford JS, Burton M, Davies P. Time and lateral tilt at Caesarean section. Br J Anaesth. 1972 May;44(5):477-84.  Lee AJ, Landau R, Mattingly JL, Meenan MM, Corradini B, Wang S, Goodman SR, Smiley RM. Left lateral table tilt for elective cesarean delivery under spinal anesthesia has no effect on neonatal acid–base status: a randomized controlled trial. Anesthesiology. 2017;127(2):241‑249.  Jackson KL, Smiley RM, Lee AJ. Neonatal acid-base status before and after discontinuing routine left uterine displacement for elective cesarean delivery: a retrospective cohort study (2014–2017). Int J Obstet Anesth. 2025;62:104350.  You need to add a widget, row, or prebuilt layout before you’ll see anything here.

On social media, the vagus nerve often gets billed as the gateway to nervous system nirvana: It's your ticket to better rest, relaxation, and health if you “stimulate” it correctly. Where did this idea come from, and what does the research say?  Host Flora Lichtman talks with neurosurgeon Kevin Tracey, a pioneer of a field called bioelectronic medicine, which uses techniques to stimulate the nervous system with electricity. Back in the 1990s, he was the first to discover that the vagus nerve regulates the immune system and inflammation. Guest: Dr. Kevin Tracey is a neurosurgeon, and president and CEO of the Feinstein Institutes for Medical Research at Northwell Health. He is the author of The Great Nerve. Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Mia Horowitz, PhD, Tel Aviv University; Aitor Aguirre, PhD, Michigan State University, Michigan, USA; and Ying Sun, PhD, University of Cincinnati, discuss the use of organoid models in lysosomal disorder research and drug development.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session3-organoids-and-lab-grown-models-in-lysosomal-disorders/Learning ObjectivesDescribe the use of heart organoid models to better understand the pathophysiology of lysosomal disorders and its clinical relevanceDescribe the use and application of brain organoid models in neuropathic Gaucher disease research and treatmentFacultyMia Horowitz, PhD, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University.Aitor Aguirre, PhD, Associate Professor of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Chief, Division of Developmental and Stem Cell Biology (IQ), Director, MSU Stem Cell Core, Michigan State University.Ying Sun, PhD, Professor, Cincinnati Children's Hospital Medical Center, University of Cincinnati.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Mia Horowitz, PhDDr. Horowitz has no relevant financial relationships to disclose.Aitor Aguirre, PhDDr. Aguirre has no relevant financial relationships to disclose.Ying Sun, PhDDr. Sun receives research support from Enkefalos Biosciences and Yuhan Corporation.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

About a year ago, a research team at Stanford Engineering led by Guosong Hong published a paper about their work to use a common food dye to make mouse skin transparent. Their findings made a big splash and have the potential to provide a range of benefits in health care. You can imagine that if we have the ability to see what's going on under the skin without having to cut into it, or use radiation to get a clear look, this could improve everything from invasive biopsies to painful blood draws. We hope you'll tune in again and enjoy.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: ​​Guosong HongGuosong's Lab: THE HONG LABConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces Guosong Hong, an expert in physics, material science, and biology from Stanford University.(00:01:52) Material Science Meets NeuroscienceHow Guosong's research blends nanomaterials and brain science.(00:03:00) Why Tissue Isn't TransparentThe challenge of light penetration in biological tissues.(00:04:54) A New Approach to Tissue ClearingThe physics behind tissue transparency and refractive index manipulation.(00:07:57) UV Light and TransparencyHow manipulating UV absorption can align refractive indexes.(00:10:16) First Experiments and ResultsInitial tests that demonstrate successful tissue clearing.(00:12:19) Applications in MedicineThe potential of transparent tissues in dermatology and medical imaging.(00:14:36) Testing on Live TissueThe results of testing transparency techniques on live mice.(00:18:30) Transparency in NatureHow some species have naturally transparent tissue.(00:19:52) Human Eye and Protein TransparencyThe unique proteins that keep our lenses clear using similar physics.(00:22:24) Wireless Light Inside the BodyDeveloping ultrasound-activated light sources for tissue imaging.(00:24:55) Precision of Ultrasound LightHow precisely ultrasound can trigger tiny particles to emit light.(00:28:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What does it mean to see beneath the surface — of the human body, the brain, or even the universe itself? In his new book, The Future of Seeing: How Imaging Is Changing Our World, Prof. Daniel Sodickson of NYU explores the future of imaging: How technology is transforming not just medicine, but our very ways of perceiving the world. With the rise of AI-driven “digital vision,” Sodickson, a pioneer of MRI innovation, argues that imaging is no longer just a diagnostic tool — it's becoming a new language of discovery.In this conversation, Sodickson explores the promises and pitfalls of this promising new technology. Reflecting on the history of scientific discovery, we examine what the next generation of imaging might reveal about life itself. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Madeline chats with Edmund Lazzari, a professor in the Catholic Studies department at Duquesne University. During their conversation, they discuss the kinds of questions that science and theology ask, the value of a liberal arts education, the Inkwells and Anvils writing community, what it means to be interdisciplinary, the importance of knowing something's purpose/function, his time in seminary, what he learned from his time as a FOCUS missionary, the importance of philosophy, experiencing beauty and majesty for yourself, and so much more.During the course of their conversation, they make many references which you can explore. Some of these references include the Story of Salvation bible study, the USCCB's Ethical and Religious Directives for Hospitals link, Biomedicine and Beatitude by Fr. Nicanor Austriaco, OP. You can also check out some of Edmund's book on natures here.Feel free to like, subscribe, and share the episode! Follow us on Instagram! @sbltfpodcastDon't forget to go out there, and be a light to this world!

Prior to coming to NYU, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. He has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics; the University of Pittsburgh; and Columbia University. He received his PhD from Columbia University. Dr. Caplan is the author or editor of 35 books and more than 880 papers in peer reviewed journals. His books include Vaccination Ethics and Policy, with Jason Schwartz, and, Getting to Good: Research Integrity in Biomedicine, with Barbara Redman. He has served on a number of national and international committees including as the chair of the National Cancer Institute Biobanking Ethics Working Group; chair of the Advisory Committee to the United Nations on Human Cloning; and chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the Special Advisory committee to the International Olympic Committee on Genetics and Gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and as the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts.

This episode is brought to you by Caldera Lab, State & Liberty, and Joi & Blokes. We are joined today by functional health coach Vince Pitstick. He delves into the intricate relationship between success and well-being, exploring the interplay of psychology, genetics, and nutrition. The episode covers a wide array of topics, from the effects of the "warrior gene" on dopamine metabolism and the challenges of anhedonia in high achievers, to the benefits of a diverse and seasonally adjusted diet. Vince also shares his personal journey overcoming OCD and addiction, illustrating the power of functional medicine and holistic approaches in achieving sustainable success and mental wellness. This episode is your comprehensive guide to unlocking your full potential by harmonizing physical, mental, and spiritual growth. Follow Vince @vince_pitstick Follow Chase @chase_chewning ----- In this episode we discuss... (00:00) Psychology and Physiology of Success (11:59) Link Between Biology, Genes, and Personalized Success (17:35) Build Your Best Diet and Nutrition Diversity (27:29) Why You Need Diet Variation (39:09) Optimizing Health With Lab Analysis (54:49) Integrating Functional Medicine (01:05:04) Balancing Fitness, Health and Success (01:12:10) Building a Foundation Before Optimizing (01:23:52) Benefits of Peptides in Biomedicine (01:32:10) Peptides cont'd, Cancer Risk, and GLP-1 (01:38:51) Metformin and Adaptation in Health (01:46:48) The Metabolic Impact of Chronic Dieting (01:54:57) Ever Forward ----- Episode resources: Save 20% on any men's skincare item with code EVERFORWARD at https://www.CalderaLab.com Save 15% on performance menswear that fits athletic build guys with code EVERFORWARD at https://www.StateAndLiberty.com  Save 10% on any labs with code CHASE at https://www.JoiAndBlokes.com  Watch and subscribe on YouTube Learn more about Vince at VidalCoaching.com

In 2019, a study from Denmark by Hviid, et al, purported to demonstrate that there was no link between the MMR vaccine and autism, even among genetically susceptible populations.The study was strongly critiqued at the time, and now, journalist Jeremy R. Hammond, along with Dr. Brian Hooker and Dr. Jeet Varia, has published a paper that addresses the serious flaws in Hviid et al, in the Journal of Biotechnology and Biomedicine. I talk with Jeremy about Hviid et al, and about his own paper, and about the state of research into the connection between vaccines and autism more broadly.Links:Hviid et al. 2019Jeremy's paperThis article summarizes key points from Jeremy's paper:I discussed medical licensing with Jeremy here.Jeremy exposes the WaPo's Lena Sun here....and the AAP's “vaccines do not cause autism” claim, here.Jeremy's book, "The War on Informed Consent" is one of the most concise and informative works on the suppression of science and discussion regarding vaccines.https://www.jeremyrhammond.com/product/the-war-on-informed-consent/You can find Jeremy here, and here. 

Read the full article for this interview here: https://oncdata.com/standard-model-biomedicine Artificial intelligence (AI) is rapidly transforming the landscape of oncology, offering new tools to improve patient care and accelerate research. In this episode of Exploring AI in Oncology, Dr. Waqas Haque sat down with Kevin Brown, Founder and CEO of Standard Model Biomedicine, to discuss the challenges and opportunities of implementing AI in cancer care.

Can science turn any blood into a universal donor type? Join us in this episode as we explore groundbreaking healthcare innovations with Maher Abou Hachem, a distinguished Professor in the Department of Biotechnology and Biomedicine at the Technical University of Denmark. Maher's expertise spans recombinant protein production, purification, biomolecular interactions, stability, and enzymology. From gut microbiome studies to pioneering blood type conversion, his cutting-edge research is reshaping the future of healthcare. Are you ready to find out what makes Maher's work so unique? Hit play to find out! Dive in now to discover: What the major blood types are, and how they are used in transfusion and transplant applications. What happens if you give the wrong blood type to a patient. How researchers can change one blood type to another. The significance of red blood cells in the human body. You can learn more about Maher and his investigations here! Episode also available on Apple Podcasts: http://apple.co/30PvU9

On this episode host Justin Barnes recorded live at HIMSS25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests.This week his guests are Adam Resnick, Director of the Center for Data Driven Discovery in Biomedicine, The Children's Hospital of Philadelphia (CHOP), and Aneesh Chopra, Author, Innovator, Former U.S. CTO, CSO at Arcadia. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Many of us are lucky to grow older, and in Europe there is an aging demographic. With this come the diseases of aging such as dementia. For a long time people have thought this inevitable but we will learn today that, as with so many diseases, lifestyle changes from a young age can counteract this, to reduce the risk of getting dementia and also stabilising mental decline. In 2021, 20.8% of the EU population was aged 65 years or older. In 2019, an Alzheimer Europe report on the prevalence of dementia estimated that there were about 9 million people living with the disease in Europe. This number is projected to double by 2050, rising towards 19 million in the European region. Globally, there are around 55 million people worldwide who are living with dementia. However, research is now showing that up to 45% of dementias could be prevented: by addressing a range of modifiable risk factors, at different stages of our lives. My guests today are: Dr. Ange Bradshaw: Director for Research at Alzheimer's Europe Dr. Joëlle Fritz: Research and Strategy Specialist, Luxembourg Institute of Health Dr. Francesca Mangialasche: Geriatrician, Division of Clinical Geriatrics: Alzheimer Research Center Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Executive Director of the World-Wide FINGERS Global Scientific Coordinating Center at the FINGERS Brain Health Institute Hassan Fadli: Founder, 5 Ironmans Beat Alzheimer's Association The 2024 World Alzheimer's report noted that 80% of people think dementia is a normal part of ageing, and 65% of healthcare professionals. Only 2% of the population are affected by rare genetic factors but for most of us this is not the case. ‘Modifiable risk factors' can be replaced to deter and stall dementia. Francesca Mangialasce is based at the Karolinska Institute in Sweden, and also works as executive director of the ‘FINGERS' Brain Health Institute, founded by Professor Mija Kivipelto, a world renowned researcher in the field of Alzheimer's disease and Dementia. FBHI is dedicated to promoting healthy brain aging and preventing cognitive impairment and dementia through innovative multi-domain clinical research and the fast translation of these results into personalised clinical practice. Brain is our main capital, and there is so much we can do to promote brain health. Studies have show that cardiovascular and metabolic disorders such as high blood pressure, high blood cholesterol, high blood sugar or diabetes are risk factors for dementia. There are many other emerging factors such as hearing impairment, vision loss, impaired oral health.  Being mentally, physically and socially active during life is important to reduce the risk of memory problems in old age. Secondary and tertiary prevention is also really important, even at the later stages of disease with therapies including art, dance and cognitive stimulation therapy .  The FINGER study across 70 countries shows that a multi-domain approach can benefit cognition:exercise, healthy diet, cognitive training, good control of metabolic/vascular disorders, and social stimulation. Stigma Hassan Fadli's father faced stigma in the village he lived all his life. This stigma deepens the pain of the suffering, knowing you are losing ‘yourself'. It is also a burden for the caregivers at a time when family and friends need the most help to support their loved one.   Hassan promised his father to work towards breaking this stigma and founded the 5 Ironmans initiative. Hassan has also made a documentary of his advocacy work alongside the endurance sport to reach people from children in schools across Europe to the Queen of Sweden.  His aim is to bring brain health into normal conversation, break the stigma, and integrate brain health awareness into public discourse.  Luxembourg support Joëlle Fritz is working  as Research and Strategy Specialist at the Luxembourg Institute of Health where she aims to bridge research to clinical care. "Programme démence prevention" (pdp) is a programme raising awareness on modifiable risk factors for dementia prevention and promotes life style changes. PDP is an integrated prevention concept funded by Luxembourg's Ministry of Health and Social Security. PDP is currently coordinated by the Centre Hospitalier  de Luxembourg in collaboration with national institutions (Luxembourg Institute of Health and Luxembourg Centre for System's Biomedicine at the University of Luxembourg) and partner associations (listed below). It is important to start as early as possible in the prevention of dementia, and so the PDP Braincoach app was created, accessible via browser to everyone also outside Luxembourg: www.pdp-app.lu Associations related in Luxembourg: L'Association nationale des diététiciens du Luxembourg: www.andl.lu ZithaAktiv: www.zithaaktiv.lu   Club Seniors of HELP asbl: www.help.lu Club Senior “Schwaarze Wee” Dudelange:   www.schwaarzewee.lu Lëtzebuerger Verein fir Gediechtnistraining: www.lvgt.lu NEUROvitalis home and digital Info-Zenter Demenz:   www.demenz.lu Association Luxembourg Alzheimer (ala) : www.ala.lu  Longevity with health  The results are clear, for dementia and living a long life with good health: we need to put in place good habits of physical, social and mental health.  Links to the notes above: https://www.5ironmansbeatalzheimer.com www.pdp.lu https://www.alzheimer-europe.org https://fbhi.se/sv/ https://www.linkedin.com/company/fingers-brain-health-institute/ https://www.linkedin.com/in/miia-kivipelto-8a8b1b3b/ https://www.chl.lu/fr https://m3s.gouvernement.lu/en.html https://www.uni.lu/lcsb-en/ https://ki.se/en

Many of us are lucky to grow older, and in Europe there is an aging demographic. With this come the diseases of aging such as dementia and a burden on family and society for care. For a long time people have thought this inevitable but we will learn today that, as with so many diseases, lifestyle changes from a young age can counteract this, to reduce the risk of getting dementia and also stabilising mental decline. In 2021, 20.8% of the EU population was aged 65 years or older. In 2019, an Alzheimer Europe report on the prevalence of dementia estimated that there were about 9 million people living with the disease in Europe. This number is projected to double by 2050, rising towards 19 million in the European region. Globally, there are around 55 million people worldwide who are living with dementia. However, research is now showing that up to 45% of dementias could be prevented: by addressing a range of modifiable risk factors, at different stages of our lives. My guests today are: Dr. Ange Bradshaw: Director for Research at Alzheimer's Europe Dr. Joëlle Fritz: Research and Strategy Specialist, Luxembourg Institute of Health Dr. Francesca Mangialasche: Geriatrician, Division of Clinical Geriatrics: Alzheimer Research Center Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Executive Director of the World-Wide FINGERS Global Scientific Coordinating Center at the FINGERS Brain Health Institute Hassan Fadli: Founder, 5 Ironmans Beat Alzheimer's Association The 2024 World Alzheimer's report noted that 80% of people think dementia is a normal part of ageing, and 65% of healthcare professionals. Only 2% of the population are affected by rare genetic factors but for most of us this is not the case. ‘Modifiable risk factors' can be replaced to deter and stall dementia. Francesca Mangialasce is based at the Karolinska Institute in Sweden, and also works as executive director of the ‘FINGERS' Brain Health Institute, founded by Professor Mija Kivipelto, a world renowned researcher in the field of Alzheimer's disease and Dementia. FBHI is dedicated to promoting healthy brain aging and preventing cognitive impairment and dementia through innovative multi-domain clinical research and the fast translation of these results into personalised clinical practice. Brain is our main capital, and there is so much we can do to promote brain health. Studies have show that cardiovascular and metabolic disorders such as high blood pressure, high blood cholesterol, high blood sugar or diabetes are risk factors for dementia. There are many other emerging factors such as hearing impairment, vision loss, impaired oral health.  Being mentally, physically and socially active during life is important to reduce the risk of memory problems in old age. Secondary and tertiary prevention is also really important, even at the later stages of disease with therapies including art, dance and cognitive stimulation therapy .  The FINGER study across 70 countries shows that a multi-domain approach can benefit cognition:exercise, healthy diet, cognitive training, good control of metabolic/vascular disorders, and social stimulation. Stigma Hassan Fadli's father faced stigma in the village he lived all his life. This stigma deepens the pain of the suffering, knowing you are losing ‘yourself'. It is also a burden for the caregivers at a time when family and friends need the most help to support their loved one.   Hassan promised his father to work towards breaking this stigma and founded the 5 Ironmans initiative. Hassan has also made a documentary of his advocacy work alongside the endurance sport to reach people from children in schools across Europe to the Queen of Sweden.  His aim is to bring brain health into normal conversation, break the stigma, and integrate brain health awareness into public discourse.  Luxembourg support Joëlle Fritz is working  as Research and Strategy Specialist at the Luxembourg Institute of Health where she aims to bridge research to clinical care. "Programme démence prevention" (pdp) is a programme raising awareness on modifiable risk factors for dementia prevention and promotes life style changes. PDP is an integrated prevention concept funded by Luxembourg's Ministry of Health and Social Security. PDP is currently coordinated by the Centre Hospitalier  de Luxembourg in collaboration with national institutions (Luxembourg Institute of Health and Luxembourg Centre for System's Biomedicine at the University of Luxembourg) and partner associations (listed below). It is important to start as early as possible in the prevention of dementia, and so the PDP Braincoach app was created, accessible via browser to everyone also outside Luxembourg: www.pdp-app.lu Associations related in Luxembourg: L'Association nationale des diététiciens du Luxembourg: www.andl.lu ZithaAktiv: www.zithaaktiv.lu   Club Seniors of HELP asbl: www.help.lu Club Senior “Schwaarze Wee” Dudelange:   www.schwaarzewee.lu Lëtzebuerger Verein fir Gediechtnistraining: www.lvgt.lu NEUROvitalis home and digital Info-Zenter Demenz:   www.demenz.lu Association Luxembourg Alzheimer (ala) : www.ala.lu  Longevity with health  The results are clear, for dementia and living a long life with good health: we need to put in place good habits of physical, social and mental health.  Links to the notes above: https://www.5ironmansbeatalzheimer.com www.pdp.lu https://www.alzheimer-europe.org https://fbhi.se/sv/ https://www.linkedin.com/company/fingers-brain-health-institute/ https://www.linkedin.com/in/miia-kivipelto-8a8b1b3b/ https://www.chl.lu/fr https://m3s.gouvernement.lu/en.html https://www.uni.lu/lcsb-en/ https://ki.se/en

Prescription medications are fairly controversial these days – cost, insurance coverage, efficacy, and too often, medications are dosed incorrectly, cause toxic side effects or just don't work. But what if we could change how we prescribe drugs, what if there was a 3D printer that could design pills that adapt to an individual's needs, and maybe print-on-demand the medications tailored to the patient? Or what if there was a real-world device that worked like the diagnostic Tricorder we imagined watching Star Trek? How about AI-infused antiviral discoveries and laboratory-level diagnostic tools accessible via your smartphone?  These ideas and technologies, and many more, are paving the way to a more democratized, connected and data-driven future of medicine, and personalized care. And this is the world where Dr. Daniel Kraft thrives. Daniel is a Stanford and Harvard trained physician-scientist with more than 25 years of experience in clinical practice, biomedical research, and innovation. He is Founder and Chair for NextMed.Health, a program which explores convergent, rapidly developing technologies and their potential to reshape the future of health and biomedicine, and he is the Faculty Chair for Medicine at Singularity University.  I'm not sure if we can call Daniel a medical futurist, as he seems to be a co-creator of that future, but I asked about what some of the various technologies transforming patient care in the next decade may be, as well as some of the exciting innovations he's seen in regenerative medicine and stem cell therapies recently. Daniel had a great deal to say about his thoughts on that vis-à-vis personalized medicine.  We wrapped up with Daniel sharing who's influenced you him and his work, and the various mentors he had in his various areas of interest. He also shared advice for young medical professionals interested in innovation and entrepreneurship. Daniel's work and life are a testament to the benefit that cross-disciplinary approaches, augmented by technological innovations, can bring to medicine and healthcare. While Daniel's work saves lives, he also serves as an inspiration for all of us to live our lives more fully.

When Spela completed her PhD in Biomedicine, she did not expect doula work to be her destiny. After years in this field and studying multiple specialized pathways, she knows in her heart that doulas make a difference not only for our clients, but also within communities. Through our conversation you will not only hear Spela's passion for birth work, but also some amazing stories about working as a doula in the country of Slovenia! Spela's leadership in her country, within the European Doula Network, and in the broader doula community worldwide is remarkable, and she's incredibly fun to chat with too. This conversation will leave you inspired! 

For our landmark 50th episode, we've got a special treat! We welcome back our friend of the podcast, Jaime Garcia-Iglesias, to discuss DoxyPEP. Plus, we're sharing the initial conversations from our World AIDS Day roundtable, recorded on November 29th, 2024. Join Jaime and chair Chase Ledin as they explore the emergence of DoxyPEP in UK sexual healthcare, and discuss the hopes and concerns surrounding its implementation.Episode GuestJaime Garcia-IglesiasJaime is a Mildred Baxter Postdoctoral Research Fellow at the Centre for Biomedicine, Self and Society at The University of Edinburgh. Jamie is working on exploring how sexual fantasies and desires can be harnessed for HIV prevention by engaging with a range of stakeholders.Additional Information and Links CW Plushttps://www.cwplus.org.uk/HIV Matters Bookstorehttps://uk.bookshop.org/shop/HIVMattersHow to contact the show Hello@hivmatterspodcast.co.ukhttps://hiv-matters.captivate.fm

Materials scientist and physicist Guosong Hong is an expert in getting materials to do remarkable things. Recently, he and collaborators used a common food dye found in snack chips to turn living tissue transparent, allowing light to penetrate through skin and muscle. Hong is now working to realize a new age of medical imaging that lets doctors see deep into the body – without surgery. It's a miracle of physics but it could change medicine, Hong tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: ​​Guosong HongGuosong's Lab: THE HONG LABConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces Guosong Hong, an expert in physics, material science, and biology from Stanford University.(00:02:52) Material Science Meets NeuroscienceHow Guosong's research blends nanomaterials and brain science.(00:04:01) Why Tissue Isn't TransparentThe challenge of light penetration in biological tissues.(00:05:55) A New Approach to Tissue ClearingThe physics behind tissue transparency and refractive index manipulation.(00:08:57) UV Light and TransparencyHow manipulating UV absorption can align refractive indexes.(00:11:17) First Experiments and ResultsInitial tests that demonstrate successful tissue clearing.(00:13:19) Applications in MedicineThe potential of transparent tissues in dermatology and medical imaging.(00:15:36) Testing on Live TissueThe results of testing transparency techniques on live mice.(00:19:30) Transparency in NatureHow some species have naturally transparent tissue.(00:20:52) Human Eye and Protein TransparencyThe unique proteins that keep our lenses clear using similar physics.(00:23:24) Wireless Light Inside the BodyThe development of ultrasound-activated light sources for tissue imaging.(00:26:56) Precision of Ultrasound LightHow precisely ultrasound can trigger tiny particles to emit light.(00:29:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

HIV Matters dives into the world of dating apps and their impact on the HIV community. Michelle sits down with Jaime Cortez-Garcia to explore how these platforms are changing the landscape of dating, relationships, and stigma for people living with HIV.Episode GuestJaime Garcia-CortezJaime is a Midred Baxter Postdoctoral Research Fellow at the Centre for Biomedicine, Self and Society at The University of Edinburgh. Jamie is working on exploring how sexual fantasies and desires can be harnessed for HIV prevention by engaging with a range of stakeholders.Additional Information and Links CW Plushttps://www.cwplus.org.uk/HIV Matters Bookstorehttps://uk.bookshop.org/shop/HIVMattersHow to contact the show Hello@hivmatterspodcast.co.ukhttps://hiv-matters.captivate.fm

Geophilia is an institute dedicated to understanding the science of space harmonics. It links the invisible forces that govern Nature with our physical reality and propose ways to make them more coherent, healthier. And we all know that with healthy spaces always comes a wealthier approach of life. Sacred temples are located in sacred spots. Thus, there is a meaning, a potent meaning that connects the invisible with the visible forces of Nature. There is a link from the inside to the outside, from the big scale to the small scale. This link is fractality. The ability our Universe has to reproduce similar patterns across different scales. Biomedicine, Geophysics, and Architecture are standard parts of knowledge that are not integrated. But in our physical reality, they are! So we study them for an extended period and make them available to the vast majority of people that like you have been researching in different fields without finding a convincing answer. This may be a possible answer that can lead you to a new beginning.A thousands myriad of opportunities open up as soon as the bird of knowledge and curiosity opens its wings to touch the sky and the earth. Through a series of books to come, you will walk with us on this journey and will be able to discover the Geophilia`s Spot. Learn how to locate them in your land, in your country, in our planet, in a similar way as ancient civilization did but now with the precious help of scientific measurements and very sensitive and advanced technology.Lydia is a Greek Architect and Wellness Coach, with a focus on the relation of buildings on health and well-being. She holds a Ph.D. in Physiology on the subject of the effect on geophysical anomalies on biology and has published in peer-review journals and conferences. She has been researching for 15 years the relation of ancient temples and their location. She is the creator of Healing Architecture and cofounder of Geophilia Institute.https://geophilia.org/Become a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

Support the show to get full episodes and join the Discord community. Joe Monaco and Grace Hwang co-organized a recent workshop I participated in, the 2024 BRAIN NeuroAI Workshop. You may have heard of the BRAIN Initiative, but in case not, BRAIN is is huge funding effort across many agencies, one of which is the National Institutes of Health, where this recent workshop was held. The BRAIN Initiative began in 2013 under the Obama administration, with the goal to support developing technologies to help understand the human brain, so we can cure brain based diseases. BRAIN Initiative just became a decade old, with many successes like recent whole brain connectomes, and discovering the vast array of cell types. Now the question is how to move forward, and one area they are curious about, that perhaps has a lot of potential to support their mission, is the recent convergence of neuroscience and AI... or NeuroAI. The workshop was designed to explore how NeuroAI might contribute moving forward, and to hear from NeuroAI folks how they envision the field moving forward. You'll hear more about that in a moment. That's one reason I invited Grace and Joe on. Another reason is because they co-wrote a position paper a while back that is impressive as a synthesis of lots of cognitive sciences concepts, but also proposes a specific level of abstraction and scale in brain processes that may serve as a base layer for computation. The paper is called Neurodynamical Computing at the Information Boundaries, of Intelligent Systems, and you'll learn more about that in this episode. Joe's NIH page. Grace's NIH page. Twitter: Related papers Neurodynamical Computing at the Information Boundaries of Intelligent Systems. Cognitive swarming in complex environments with attractor dynamics and oscillatory computing. Spatial synchronization codes from coupled rate-phase neurons. Oscillators that sync and swarm. Mentioned A historical survey of algorithms and hardware architectures for neural-inspired and neuromorphic computing applications. Recalling Lashley and reconsolidating Hebb. BRAIN NeuroAI Workshop (Nov 12–13) NIH BRAIN NeuroAI Workshop Program Book NIH VideoCast – Day 1 Recording – BRAIN NeuroAI Workshop NIH VideoCast – Day 2 Recording – BRAIN NeuroAI Workshop Neuromorphic Principles in Biomedicine and Healthcare Workshop (Oct 21–22) NPBH 2024 BRAIN Investigators Meeting 2020 Symposium & Perspective Paper BRAIN 2020 Symposium on Dynamical Systems Neuroscience and Machine Learning (YouTube) Neurodynamical Computing at the Information Boundaries of Intelligent Systems | Cognitive Computation NSF/CIRC Community Infrastructure for Research in Computer and Information Science and Engineering (CIRC) | NSF - National Science Foundation THOR Neuromorphic Commons - Matrix: The UTSA AI Consortium for Human Well-Being 0:00 - Intro 25:45 - NeuroAI Workshop - neuromorphics 33:31 - Neuromorphics and theory 49:19 - Reflections on the workshop 54:22 - Neurodynamical computing and information boundaries 1:01:04 - Perceptual control theory 1:08:56 - Digital twins and neural foundation models 1:14:02 - Base layer of computation

Parag Mallick discusses the role of AI and machine learning in biotech with special guests Vijay Pande from Andreessen Horowitz and Matt McIlwain from Madrona Venture Group. Their fascinating conversation covers:Advances that have enabled biotech to make use of AI and machine learningHow founders are applying AI and machine learning in biotechThe future of AI and machine learning in biotechChapters00:00 - Introduction04:37 - How did Vijay and Matt get into AI and ML07:33 - The importance of structured data, advances in compute, and algorithmic advances in driving the boom in machine learning18:44 - The Intersection of AI and biology21:57 - The evolution of biological models31:55 - The Complexity of biological data39:42 - Ways founders and biotech startups are using AI43:25 - Favorite/Impactful applications of AI/ML47:00 - AI for experimental design50:13 - The future of AI in bio/healthResourcesLearn more about Matt McIlwainLearn more about Vijay PandeFolding at HomeLearn about various types of machine learning on IBM's websiteLearn about autoencoders on IBM's websiteLearn more about transformers on NVIDIA's blogTranslating Proteomics Episode 6 - The Future of AI in Biomedicine

A recent Special Communication published in JAMA points out that the FDA has already approved nearly 1000 devices using AI. Author Robert M. Califf, MD, commissioner of the US Food and Drug Administration, joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss AI regulation. Related Content: FDA Commissioner Robert Califf on Setting Guardrails for AI in Health Care JAMA AI Interview With Robert M. Califf, MD FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine

Our guest this episode is Charles Fisher, co-founder and currently Chief Scientific Officer of Unlearn.AI. Unlearn has been a leader in the advancement of Digital Twins as a tool to drastically improve the efficiency of clinical trials. Not only a visionary scientist and trailblazing entrepreneur, Charles is fearless with his hot takes. So sit back and enjoy this free wheeling conversation! Episode 40 links: ⁠⁠⁠⁠⁠⁠TPM E40⁠⁠⁠ for highlights and links from this episode >⁠⁠⁠⁠ Potential of the Xerna™ TME Panel as a Predictive Biomarker (SITC 2024 Poster) ⁠⁠⁠⁠Genialis' Upcoming Events⁠⁠⁠⁠ ⁠Genialis on LinkedIn

Novichok is in the news again. An inquiry currently underway in the UK is looking into the 2018 death of 44-year-old woman Dawn Sturgess who sprayed herself with a bottle of perfume that turned out to be laced with the deadly nerve agent. Novichok is an incredibly powerful poison implicated in a series of murders over decades spritzed onto common items like umbrellas, phones and door handles. Where did this incredibly powerful poison come from – and how exactly does it kill you and who has been using it and why? Doctor Ian Musgrave is a senior lecturer at the School of Biomedicine at the University of Adelaide. He joins Bension Siebert to unpack the toxicology behind the headline. Follow The Briefing:TikTok: @listnrnewsroomInstagram: @listnrnewsroom @thebriefingpodcast YouTube: @LiSTNRnewsroomFacebook: @LiSTNR NewsroomSee omnystudio.com/listener for privacy information.

Павел Лисицын — биолог и популяризатор научного знания о многообразии животного и растительного мира. Аспирант Института биологии и биомедицины ННГУ им. Лобачевского, лауреат премии «ТОП 50. Самые знаменитые люди Нижнего Новгорода 2023». Pavel Lisitsyn is a biologist and a science communicator, specializing in the diversity of the animal and plant world. He is a PhD candidate at the Institute of Biology and Biomedicine at Lobachevsky University, and a recipient of the "TOP 50. Most Famous People of Nizhny Novgorod 2023" award. FIND PAVEL ON SOCIAL MEDIA Instagram | TikTok | Telegram ================================== SUPPORT & CONNECT: Support on Patreon: ⁠⁠https://www.patreon.com/denofrich⁠⁠  Twitter: ⁠⁠https://twitter.com/denofrich⁠⁠  Facebook: ⁠⁠https://www.facebook.com/mark.develman/⁠⁠  YouTube: ⁠⁠https://www.youtube.com/denofrich⁠⁠  Instagram: ⁠⁠https://www.instagram.com/den_of_rich/⁠⁠  Hashtag: #denofrich Type of unconscious: 11 © Copyright 2024 Den of Rich. All rights reserved.

In this episode with Alex Tarnava, you'll get to dive into the fascinating world of molecular hydrogen and its powerful health benefits. Alex shares his personal journey from battling arthritis to discovering hydrogen's potential for gut repair and overall well-being. You'll also explore how hydrogen works as a mitohormetic agent, boosts mitochondrial health, and upregulates your body's antioxidant defenses. Alex also breaks down cutting-edge research, reveals the science behind hydrogen tablets, shares insights on dosing, and much more! Alex Tarnava, the inventor of the molecular hydrogen tablet, leads the clinical and preclinical outreach programs for its development and research. He has published a significant number of papers on the subject through peer review, including numerous papers coauthored with my friend and former podcast guest, Dr. Tyler LeBaron (who I interviewed in the episode "The 30-Year-Old Scientist Phenom Who Runs a 2:30 Marathon, Deadlifts 420 Pounds & Drinks Hydrogen Enriched Water"). Alex places a great deal of emphasis on why dose and concentration are important for hydrogen tablet use. He was even invited to present at the 1st Annual European Conference for Hydrogen in Biomedicine. His presentation on dosing conversions from translational to clinical research, and the discrepancies between successful rodent studies and human studies, was selected to be included in the course material for the pharmaceutical program at a university in Slovakia. Tune in to explore how embracing hydrogen could transform your well-being and support your journey toward a healthier, more vibrant life! Full Show notes: https://bengreenfieldlife.com/hydrogenalex Episode Sponsors:  Organifi: Go to Organifi.com/Ben for 20% off your order. CAROL Bike: For a limited time, you can get $250 off yours with the code BEN. Don't wait any longer, join over 25,000 riders and visit carolbike.com/ben today.  Timeline Nutrition: Go to timelinenutrition.com/BEN and use code BEN to get 10% off your order. Lagoon: Go to LagoonSleep.com/BEN and use the code BEN for 15% off your first purchase. BIOptimizers Mushroom Breakthrough: Go to bioptimizers.com/ben now and enter promo code BEN10 to get 10% off any order.See omnystudio.com/listener for privacy information.

Season Two of playing god? is coming soon. Here's a preview of what's in the works.

Imagine a world where the ability to speak and express thoughts and emotions is lost. How would someone navigate life in silence, cut off from the power of their own voice? This is the stark reality for individuals who suffer from near-complete paralysis, where communication becomes an overwhelming challenge. But what if there was a way to give these individuals their voice back—not just restoring speech but recreating the unique qualities of their pre-injury voice? On this episode of the BCI Award series of Neurocareers: Doing the Impossible!, we explore this groundbreaking possibility with our guest, Kaylo Littlejohn, an EECS PhD student at UC Berkeley. Kaylo, advised by Professor Gopala K. Anumanchipalli and Dr. Edward F. Chang, has been at the forefront of developing revolutionary AI systems that translate neural activity into spoken or written words. His research focuses on restoring lost functions to those with severe paralysis through speech and avatar neuroprostheses. Remarkably, Kaylo's work enabled the first-ever demonstration of intelligible speech synthesis from neural activity in a person who had lost the ability to communicate. Working alongside his team at UC Berkeley and UCSF, Kaylo has helped create a neuroprosthesis capable of not only decoding speech but also controlling a virtual avatar that mirrors the user's facial expressions and emotions. This technology has already received global recognition, having been featured in Nature, on the front cover of The New York Times, and showcased at White House Demo Day. Their innovative project earned 2nd place in the prestigious BCI Award 2023. Join us as we dive into the story behind this life-changing technology, the challenges faced along the way, and the future of AI-driven neuroprosthetics. Kaylo Littlejohn shares his journey, the cutting-edge science behind their success, and how they are truly doing the impossible by giving people back their voices—literally. A listener's feedback from this interview: "I was very moved by Kaylo's story of using his patient's wedding video to recreate her voice. What an incredible gift to her and her husband!" About the Podcast Guest: Kaylo Littlejohn is an EECS Ph.D. student at UC Berkeley, advised by Professor Gopala K. Anumanchipalli and Dr. Edward F. Chang. His research is focused on restoring lost function to those who have severe paralysis via the use of speech and avatar neuroprostheses. Kaylo's research enabled the first demonstration of intelligible speech synthesis from neural activity in a person who has lost the ability to communicate. About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a neuroscience educator, research consultant, and career coach for people in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities job applicants face in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume, and cover letter development Neurotech / neuroscience job interview preparation and practice Networking strategies to connect with professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news

The powerful gene editing tool CRISPR is already being tested on animal and plant cells. It has even been used on humans. How might this revolutionary tool change our lives? On the one hand, it could cure inherited diseases and rid the world of malaria-spreading mosquitoes. On the other hand, scientists using it are accelerating evolution and introducing novel genetic combinations that could transform our biological landscape in unforeseen ways. We explore the ramifications of this revolutionary technology. Guests: Nathan Rose – Molecular biologist and head of malaria programs at U.K. based biotech company, Oxitec. Hank Greely – Law professor and director of the Center for Law in the Biosciences at Stanford University and author of “CRISPR People: The Science and Ethics of Editing Humans.” Antonio Regalado – Senior Editor for Biomedicine, MIT Technology Review. *Originally aired April 17, 2023 Featuring music by Dewey Dellay and Jun Miyake Big Picture Science is part of the Airwave Media podcast network. Please contact advertising@airwavemedia.com to inquire about advertising on Big Picture Science. You can get early access to ad-free versions of every episode by joining us on Patreon. Thanks for your support! Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode of Christopher Lochhead: Follow Your Different, we engage in a captivating discussion with neuroscientist and author, Kelly Clancy. We explore the profound impact of games on human behavior and society, highlighting their dual nature as both trivial pastimes and cognitive tools. Kelly delves into how games shape intelligence, social structures, and even political systems. The conversation also touches on the gamification of life, the role of games in learning and social bonding, and the potential benefits and pitfalls of gaming. This episode offers a fresh perspective on the universal appeal and transformative power of games. You're listening to Christopher Lochhead: Follow Your Different. We are the real dialogue podcast for people with a different mind. So get your mind in a different place, and hey ho, let's go. Kelly Clancy on the Dual Nature of Games Kelly Clancy introduces the concept of the dual nature of games, highlighting their role as both simple entertainment and complex cognitive tools. Games are often dismissed as mere pastimes, but they serve as mental scaffolding that helps individuals understand and navigate complex social systems. Games have played a significant role throughout history, shaping intelligence and social structures. From ancient board games to modern video games, they have been instrumental in teaching strategic thinking, cooperation, and competition. Understanding Complex Social Systems through Games Christopher and Kelly discuss how games serve as a framework for understanding societal rules and structures. Games like Monopoly can illustrate the foundational thinking behind economic systems such as capitalism and socialism. Kelly emphasizes the universal nature of play across species and its evolutionary significance. Games are not just a human phenomenon; they are observed in various animal species, highlighting their fundamental role in development and social bonding. Games as Tools of Learning Throughout history, games have been used as tools for conflict resolution and social bonding. They provide a structured environment for competition and cooperation, helping to resolve disputes and build relationships. Uncertainty is also a key aspect of games that captivates the brain and drives learning. The unpredictability of outcomes keeps players engaged and motivated to improve their skills. Games also serve as a window into understanding human behavior. The spectator element of games, such as watching sports or eSports, allows individuals to observe and analyze the actions and strategies of others. To hear more from Kelly Clancy and the hidden power of Games, download and listen to this episode. Bio Kelly Clancy is a distinguished neuroscientist and author, known for her contributions to understanding biological information processing and agency. Her research has been funded by prestigious fellowships, including those from HFSP, EMBO, and the Branco Weiss Fellowship. Kelly's work delves into the principles of sensory representations and the interplay between agency and sensory perception in the brain. She has published extensively in top scientific journals and has received the Regeneron Prize for Innovation in Biomedicine. Kelly's debut book, Playing with Reality: How Games Have Shaped Our World, explores the impact of games on human cognition and society. Her essays have been featured in renowned publications such as Harper's Magazine, Wired, and The New Yorker, reflecting her talent for making complex scientific concepts accessible and engaging to the public. Her interdisciplinary approach bridges neuroscience and literature, making her a prominent voice in contemporary science communication​. Links Connect with Kelly Clancy! Website | X (formerly Twitter) We hope you enjoyed this episode of Christopher Lochhead: Follow Your Different™! Christopher loves hearing from his listeners. Feel free to email him, connect on Facebook, X (formerly Twitter), Instagram,

Dr. Robert S. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT). Being one of the eight Institute Professors is the highest honor that can be awarded to a faculty member at MIT. Much of Bob's research is at the interface between materials and medicine. His lab has created nanoparticles and drug delivery systems, engineered tissues and organs for things like artificial skin for burn victims, and made organ-on-a-chip technology to help develop and test new drugs that may someday help patients. When he's not working, Bob enjoys spending time with his family, taking his kids to sporting events, lifting weights, and going on walks with his wife. He received his bachelor's degree in chemical engineering from Cornell University and his Sc.D. in chemical engineering from Massachusetts Institute of Technology. Afterwards, Bob worked as a postdoctoral fellow at the Children's Hospital Boston and at Harvard Medical School. He joined the faculty at MIT in 1978. Since then, Bob has accepted more than 220 major awards and honors, including the U.S. National Medal of Science, the U.S. National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, Hoover Medal, Dreyfus Prize in Chemical Sciences, BBVA Frontiers of Knowledge Award in Biomedicine, Balzan Prize, and the Dr. Paul Janssen Award. In 1998, he received the Lemelson-MIT prize, the world's largest prize for invention for being “one of history's most prolific inventors in medicine,” and he was inducted into the National Inventors Hall of Fame in 2006. He is an elected Fellow of the Institute of Medicine of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Sciences, and National Academy of Inventors, and the Royal Academy of Engineering. He has been awarded over 1,000 patents and has received 42 honorary doctorate degrees, including degrees from Harvard, Yale, Columbia, and Northwestern. In our conversation, he shares more about his life and science.

AI might be the biggest buzz word of the decade, but the buzz is warranted in terms of its practical potential in biological research. In this episode of Translating Proteomics, Parag and Andreas discuss some of the early wins for AI in biology, practical ways AI can be applied to biology research in the near term, challenges in that application, and how proteomics researchers in particular can use AI to advance their work.Chapters:00:00 – Why now is the time to apply AI to biomedicine05:28 – Difficulties and potential solutions when applying AI to biology14:20 – How AI will impact the study of proteins19:34 – Risks of AI in biomedicine

Can science turn any blood into a universal donor type? Join us in this episode as we explore groundbreaking healthcare innovations with Maher Abou Hachem, a distinguished Professor in the Department of Biotechnology and Biomedicine at the Technical University of Denmark. Maher's expertise spans recombinant protein production, purification, biomolecular interactions, stability, and enzymology. From gut microbiome studies to pioneering blood type conversion, his cutting-edge research is reshaping the future of healthcare. Are you ready to find out what makes Maher's work so unique? Hit play to find out! Dive in now to discover: What the major blood types are, and how they are used in transfusion and transplant applications.  What happens if you give the wrong blood type to a patient.  How researchers can change one blood type to another.  The significance of red blood cells in the human body. You can learn more about Maher and his investigations here! Take advantage of a 5% discount on Ekster accessories by using the code FINDINGGENIUS. Enhance your style and functionality with premium accessories. Visit bit.ly/3uiVX9R to explore latest collection. Episode also available on Apple Podcasts: http://apple.co/30PvU9

Enjoy this episode? Please share it with at least ONE friend who you think needs to hear it! Join us as we dive into the fascinating world of holographic blood, pleomorphism, bacteria, and the intricacies of bodily structures. Key Discussion Points: Holographic Blood: Learn about the true nature of our blood and its incredible, other-worldly properties with respect to our health. Pleomorphic Cycle: Delve into the pleomorphic cycle and understand its significance in the body. Role of Bacteria: Learn about the role of bacteria, the idea that there is only one type, and how they contribute to health. Darkfield Microscopy: Learn about darkfield microscopy and the ability to locate specific ailments via analyzying the blood. Nanobots Mischaracterization: Discuss the mischaracterization of self-forming nanobots and the importance of accurate scientific communication. Hierarchy of Energy, Inflammation, and Matter: Examine the hierarchy of energy, inflammation, and matter in understanding health and disease.   About Adam Bigelsen and Ana Maria Oliva: Adam Bigelsen is the CEO of the Bigelsen Academy, an international speaker, and a Terrain Paradigm learning facilitator. He keeps their method current with the latest research and technology in Holographic Blood® readings. Based in Mexico, Adam and his team offer the Bigelsen Method, and he also works in sound therapy. Ana Maria Oliva holds a PhD in Biomedicine and a Master's in Biomedical Engineering. She has a background in NanoBioEngineering and has studied the effects of electromagnetic fields on cells. Her expertise includes drug delivery systems, microbiology, and nanotechnology, connecting medicine with engineering. For more information, visit: Bigelsen Academy: www.BigelsenAcademy.com  Ana Maria Oliva: www.AnaMariaOliva.es  Support Terrain: www.SupportTerrain.com University of Terrain: www.UniversityOfTerrain.com   The Way Forward podcast is sponsored by: NEW BIOLOGY CLINIC: Experience individually tailored terrain-based health services with virtual consults, practitioner livestreams, movement classes, and more. The New Biology Clinic's motivation is to make you healthy and keep you that way. Visit https://NewBiologyClinic.com and enter code TheWayForward for $50 off your activation fee. Members of The Way Forward get the full activation fee waived. Become a member of The Way Forward here: https://thewayfwrd.com/membership-sign-up/ ————————— ORGANIC MUSCLE: Organic Muscle is revolutionizing sports nutrition by exclusively utilizing non-GMO ingredients from USDA Organic farms. Experience the fusion of organic purity and scientific excellence at https://organicmuscle.com, and unlock a 15% discount with code "FORWARD15" at checkout. ————————— BIOPTIMIZERS: Magnesium Breakthrough from Bioptimizers delivers 7 different forms of magnesium, free from additives, and made with the highest quality all-natural ingredients. Treat your mind and body to this full-spectrum solution. Visit https://bioptimizers.com/alec and use promo code "ALEC10" at checkout! ————————— For more on The Way Forward, please visit: https://thewayfwrd.com Visit our online marketplace for discounts on a variety of the best holistic health brands and products: https://thewayfwrd.com/store/ For all of our links, visit: https://www.flowcode.com/page/thewayforward Support The Way Forward and Alec's work: https://thewayfwrd.com/donate/ FIND YOUR PEOPLE! Join The Way Forward to connect with like minded men and women near you, businesses near you, and more! The best part? You pay whatever you want!: https://thewayfwrd.com/membership-sign-up/ Do you run a freedom-oriented or holistic health-oriented business? Join our FREE business directory here: https://thewayfwrd.com/directory-form/ You can watch The Way Forward Podcast on YouTube, Unite, Bitchute & Rumble Youtube: https://www.youtube.com/@TheWayFwrd Unite: https://unite.live/channels/the-way-forward/the-way-forward Bitchute: https://www.bitchute.com/channel/a3s3CiyELVd8/ Rumble: https://rumble.com/user/TheWayFwrd ————————— *This material may not be published, broadcast, rewritten or redistributed in whole or in part without expressed written permission from The Way Forward, LLC. The purpose of this presentation is to convey information. It is not intended to diagnose, treat or cure a condition; nor is it to be considered medical or legal advice, opinion or recommendation. This information is presented in the spirit of service for all.*   0:00 - Holographic Blood & Unfounded Nanobot Fear 1:46 - Introduction  5:55 - Adam's Background and Start 18:24 - Microscopic Images of Bodily Structures in the Blood 22:00 - Meeting Ana Maria in Spain  41:28 - What Are Nanobots? 47:07 - Images Around Transhumanism and Fear 57:05 - Vaxxed vs. Unvaxxed Psyop 1:08:08 - Microscopic Images of Stem Cells 1:19:10 - No One Knows 100% 1:28:25 - The Patterns of Disease  1:37:08 - 1 Type of Bacteria Only Exists 1:42:28 - Innate Abilities 1:51:05 - Education and Empowerment 2:04:20 - Moving Forward  2:06:11 - Closing Thoughts  

EPISODE SUMMARY Join scientist and mindset & high-performance coach Claudia Garbutt and accomplished aging researcher José Pedro Castro, PhD, as they discuss aging and health In this episode, we talk about: - What is aging & age-related inflammation - Good inflammation VS bad inflammation - Aging clocks and important biomarkers     Episode NOTES José Pedro Castro completed his PhD in Biomedicine in 2015 by Universidade do Porto Faculdade de Medicina. He then moved to the German Institute of Human Nutrition and joined the Grune Lab (Berlin, Germany) to study how age-related redox and metabolism changes impact the adipose tissue and skeletal muscle.  After completing his aims, he was awarded with the prestigious DFG Max-Kade fellowship and moved to Harvard Medical School (Boston, USA) where he joined the Gladyshev Lab. There, he explored the genetics of aging, age-related diseases and lifespan control from a systems biology perspective.  Recently, and after returning to Portugal, he has joined Logarinho Lab at I3S (Porto, Portugal) after being awarded with the FCT CEEC 5th Edition for Assistant Researcher. Published over 30 articles in peer-reviewed journals such as Cell, Nature Aging or Science Advances. Has received several awards and/or honors, including Early Research Career Award (2010) and Young Investigator Award (2013). He is a reviewer for several scientific journals and a review editor for Redox Biology and Frontiers in Aging. His focus lies on understanding the biology of aging and age-related diseases. Using a combination of experimental and computational approaches he is keen to unravel age-related molecular trajectories leading to chronic diseases.  He is also an assistant professor for Immunology and an invited professor for Biogerontology and Aging and Nutrition. He is involved in several dissemination activities such as the creation of the Portuguese Society for Science and Medicine of Longevity.  On a more personal note, José also dedicates his time to literature by reading as much as he can and writing short fiction stories, but his true desire is to one day write a full novel!   Links: https://www.linkedin.com/in/jos%C3%A9-pedro-castro-phd-92528620   ------------ Click this link to listen on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess   Help me keep this show running and awesome: Hit subscribe and join the tribe! THANK YOU for your support! 

HEALTH NEWS   ·         Melatonin helps prevent weight gain in preclinical research ·         Dietary treatment more effective than medicines in IBS ·         New England seafood loaded with more toxic ‘forever chemicals' than realized, especially shrimp and lobster ·         Nattokinase Dissolves Fibrinaloid Microclots ·         Protecting brain cells with cannabinol: Research suggests CBN shows promise for treating neurological disorders ·         Research explores how a father's diet could shape the health of his offspring       Melatonin helps prevent weight gain in preclinical research University of Granada (Spain), April 17 2024 (Life Extension)  Findings from a study reported in Biomedicine & Pharmacotherapy indicated that melatonin, a hormone that induces sleep, may be helpful in the prevention of obesity. The study included 32 six-week-old rats that were bred to develop obesity and diabetes and 32 lean rats of the same age.  Obese rats that received melatonin gained less weight and had less visceral fat (central obesity) compared with obese untreated animals at the end of the 12-week period. Melatonin-treated rats also had less obesity-induced muscle fiber atrophy and showed increased mitochondrial activity, which may contribute to the decrease in weight gain observed in these animals. Additional research showed that melatonin increased a thermogenic response to cold exposure, which helps burn fat.  "During the day, it is good to expose yourself to natural light, do adequate physical activity, choose low-calorie diets loaded with unprocessed foods and replace these additives with thermogenic spices and herbs, avoid eating between meals, do not wear insulating clothing and keep the heating at a comfortable and cool temperature of around 17⁰ C, as well as showering with cool water," senior author Ahmad Agil of the University of Granada School of Medicine recommended.   Dietary treatment more effective than medicines in IBS University of Gothenburg (Sweden), April 18, 2024 (Eurekalert)  Dietary treatment is more effective than medications in irritable bowel syndrome (IBS). These are the findings of a study conducted at the University of Gothenburg. With dietary adjustments, more than seven out of ten patients had significantly reduced symptoms.  The current study, published in The Lancet Gastroenterology & Hepatology, compared three treatments: two dietary and one based on use of medications. The participants were adult patients with severe or moderate IBS symptoms at Sahlgrenska University Hospital in Gothenburg. The first group was given traditional IBS dietary advice, focusing on eating behavior combined with low intake of fermentable carbohydrates, known as FODMAPs. These include e.g. products with lactose, legumes, onions, and grains, which ferment in the colon and can cause pain in IBS. The second group received a dietary treatment low in carbohydrates and proportionally high in protein and fat. In the third group, the best possible medication was given based on the patient's most troublesome IBS symptoms. Of those who received traditional IBS dietary advice and low content of FODMAPs, 76% had significantly reduced symptoms. In the group receiving low carbohydrates and high protein and fat, the proportion was 71%, and in the medication group 58%.     New England seafood loaded with more toxic ‘forever chemicals' than realized, especially shrimp and lobster   Dartmouth College, April 17, 2024 (Study Finds) A new study out of Dartmouth College suggests that seafood from succulent lobster to flaky cod may come with an unseen risk: exposure to a class of persistent, man-made toxins known as PFAS. PFAS, short for per- and polyfluoroalkyl substances, are a family of chemicals that have been widely used in consumer products since the 1950s. You might know them best for their role in making non-stick cookware and stain-resistant fabrics, but they're also found in a host of other items, from food packaging to firefighting foams. PFAS are incredibly resistant to breaking down in the environment. They can linger for years, even decades, accumulating in soil, water, and living organisms. This persistence is particularly concerning because exposure to certain PFAS has been linked to a range of health issues, including cancer, thyroid problems, and reproductive disorders. Dartmouth researchers conducted a two-pronged study, published in the journal Exposure and Health. First, they analyzed fresh seafood samples purchased from a coastal New Hampshire market, testing for 26 different PFAS compounds. They focused on some of the most commonly consumed species in the region: cod, haddock, lobster, salmon, scallops, shrimp, and tuna. Several PFAS compounds were detected in the seafood samples, with the highest levels found in shrimp and lobster.  New Hampshire's children between two and 11 years-old in the state eat about a fifth of an ounce of seafood daily, putting them at the top end of the range for kids nationwide.   Nattokinase Dissolves Fibrinaloid Microclots University of Liverpool (UK), April 18, 2024 (BioRxiv) Post-acute sequelae after SARS-CoV-2 infection (long COVID) and after COVID-19 vaccination are characterized by micro blood clotting . The work of Scheim et al suggests the majority of syndromes in both cases are due to Spike protein mediated hemagglutination and then the development of small clots that serve the major organs in the body.   Nattokinase, from the Japanese fermented food natto, is a protease with fibrinolytic activity that can thus degrade conventional blood clots. In some cases, however, including in Long COVID, fibrinogen can polymerise into an anomalous amyloid form to create clots that are resistant to normal fibrinolysis and that we refer to as fibrinaloid microclots.  The study shows that recombinant nattokinase is effective at degrading the fibrinaloid microclots in vitro. This adds to the otherwise largely anecdotal evidence, that we review, that nattokinase might be anticipated to have value as part of therapeutic treatments for individuals with Long COVID and related disorders that involve fibrinaloid microclots.   Protecting brain cells with cannabinol: Research suggests CBN shows promise for treating neurological disorders Salk Institute, April 18, 2024 (Medical Xpress) One in every 10 individuals above the age of 65 develops an age-related neurological disorder like Alzheimer's or Parkinson's, yet treatment options remain sparse for this population. Scientists have begun exploring whether cannabinoids—compounds derived from the cannabis plant, like well-known THC (tetrahydrocannabinol) and CBD (cannabidiol)—may offer a solution. A third, lesser-known cannabinoid called CBN (cannabinol) has recently piqued the interest of researchers, who have begun exploring the clinical potential of the milder, less psychoactive substance. In a new study, scientists at the Salk Institute help explain how CBN protects the brain against aging and neurodegeneration, then use their findings to develop potential therapeutics. The researchers created four CBN compounds that were more neuroprotective than the standard CBN molecule The findings, published in Redox Biology, suggest promise for CBN in treating neurological disorders like traumatic brain injury, Alzheimer's disease, and Parkinson's disease, and also highlight how further studies of CBN's effects on the brain could inspire the development of new therapies for clinical use.   Research explores how a father's diet could shape the health of his offspring University of Sydney (Australia) April 16, 2024 New research, published in Nature Communications, finds that the macronutrient balance in the diet of male mice affects the level of anxiety-like behaviour of sons and the metabolic health of daughters. The research provides a step towards understanding how the effect of diet can transmit from one generation to the next via a father's sperm. It could ultimately inform dietary guidelines for fathers-to-be, with the goal of lowering the risk of metabolic disease and mood disorders in the next generation. At the University of Sydney's Charles Perkins Centre in Australia researchers fed male mice one of ten diets differing in the proportions of protein, fats, and carbohydrates, then allowed them to mate with females reared on standard diet. The behaviour and physiology of the resulting pups were then studied. The scientists discovered that male mice fed low protein and high carbohydrate diets were more likely to have male offspring with higher levels of anxiety, as measured by time spent in the safety zones of their maze. They also found that male mice that were fed high fat diets were more likely to have daughters with higher levels of body fat and markers of metabolic disease. “Our study shows that the type of diet eaten before conception can program specific characteristics of the next generation,” says co-senior author and leader of the GECKO consortium Professor Romain Barrès, from the University of Copenhagen and Université Côte d'Azur, Nice.

Curious about the intersection of engineering and health?In this episode of 7-8 Figure Special Series I interviewed Dr. Soumyadip Rakshit. He is the CEO & Co-Founder at MysteryVibe, world-leader in women's & men's health devices that are deeply researched, doctor-recommended, award-winning OTC medical devices to make sexual health accessible to all. We delve into the science behind the devices, the research, and the clinical trials that ensure their efficacy and safety. But this episode isn't just about the devices; it's about the impact they have on people's lives & the business side of it.If you ever wondered how tech can transform your health, check this out.Show links:MysteryVibe Website: https://world.mysteryvibe.com/Soumyadip Rakshit LinkedIn: https://www.linkedin.com/in/soum/Book a call with Michelle: https://www.AwarenessStrategies.com/m30Join our Facebook group for business owners to get help or help other business owners! The Business Ownership Group - Secrets to Scaling: https://www.facebook.com/groups/businessownershipsecretstoscalingLooking to scale your business? Get free gifts here to help you on your way: https://www.awarenessstrategies.com/

In this episode, Nathan sits down with Elicit co-founders Andreas Stuhlmüller and Jungwon Byun to discuss their mission to make AI-assisted research more accessible and reliable. Learn about their unique approach to task decomposition, which allows language models to accurately tackle complex research questions. We delve into the company's tech stack, their transition from nonprofit to startup, and their dedication to creating trustworthy AI tools for high-stakes applications. Join us for an exploration of the future of AI in research. The Cognitive Revolution is part of the Turpentine podcast network. Learn more: www.turpentine.co HELPFUL LINKS:  Elicit : https://elicit.com/ Andreas Stuhlmüller : https://twitter.com/stuhlmueller Jungwon Byun : https://twitter.com/jungofthewon SPONSORS: Oracle Cloud Infrastructure (OCI) is a single platform for your infrastructure, database, application development, and AI needs. OCI has four to eight times the bandwidth of other clouds; offers one consistent price, and nobody does data better than Oracle. If you want to do more and spend less, take a free test drive of OCI at https://oracle.com/cognitive ODF is where top founders get their start. Apply to join the next cohort and go from idea to conviction-fast. ODF has helped over 1000 companies like Traba, Levels and Finch get their start. Is it your turn? Go to http://beondeck.com/revolution to learn more. Omneky is an omnichannel creative generation platform that lets you launch hundreds of thousands of ad iterations that actually work customized across all platforms, with a click of a button. Omneky combines generative AI and real-time advertising data. Mention "Cog Rev" for 10% off www.omneky.com The Brave search API can be used to assemble a data set to train your AI models and help with retrieval augmentation at the time of inference. All while remaining affordable with developer first pricing, integrating the Brave search API into your workflow translates to more ethical data sourcing and more human representative data sets. Try the Brave search API for free for up to 2000 queries per month at https://bit.ly/BraveTCR Plumb is a no-code AI app builder designed for product teams who care about quality and speed. What is taking you weeks to hand-code today can be done confidently in hours. Check out https://bit.ly/PlumbTCR for early access. Head to Squad to access global engineering without the headache and at a fraction of the cost: head to choosesquad.com and mention “Turpentine” to skip the waitlist. TIMESTAMPS: (00:00:30) Intro (00:05:05) What is Elicit? (00:06:03) Vision for Elicit (00:10:10) Making research transparent (00:11:58) How to use it? (00:15:27) Sponsors: Oracle | On Deck | Omneky (00:18:21) Task Decomposition (00:23:48) Defining the task (00:26:30) Eliciting fine-grained evaluations (00:28:06) Hallucination rates (00:30:22) Models in play (00:31:30) Sponsors: Brave | Plumb | Squad (00:34:26) Shipping a new feature every week (00:36:10) What was not possible a year ago? (00:38:26) Chain of thought (00:43:47) Tactically, how to structure the chain of thought (00:45:21) Data sets and fine-tuning (00:51:23) Scaffolding (00:53:22) Translating structure into more compute (00:54:27) Infrastructure for investigating papers in detail (00:59:50) Emphasis on high-value use cases over speed (01:00:33) Balancing long-term safety and misuse concerns (01:02:36) Monitoring research progress for negative impact (01:06:05) Evolving user base and usage patterns (01:06:52) Biomedicine as a key domain for Elicit (01:08:57) Expanding results and depth of processing (01:11:40) Reorganizing information for better understanding (01:13:12) Habit formation and frequency of use (01:14:43) The concept of an AI bundle subscription (01:18:09) Nonprofit to Commercial Venture (01:20:08) Nonprofit Team and Commercial Mission (01:20:39) Hiring Needs at Elicit

They're not a plant or an animal — fungi are their very own kingdom of life. And their unique composition means they offer novel, often unbelievable, benefits to our health. Certain species of fungi are currently used to treat conditions ranging from cancer to depression. The love of mushrooms (or mycophilia) has grown in recent years. And at the heart of this movement is biologist Dr. Merlin Sheldrake, author of the bestseller Entangled Life: How Fungi Make Our Worlds, Change Our Minds and Shape Our Futures. In today's episode of ZOE Science & Nutrition, Jonathan, Merlin, and ZOE Co-Founder Prof. Tim Spector ask: Why are mushrooms so special?If you want to uncover the right foods for your body, head to zoe.com/podcast, and get 10% off your personalized nutrition program.Download our FREE guide — Top 10 Tips to Live Healthier: https://zoe.com/freeguide Follow ZOE on Instagram.Timecodes:00:00 - Introduction 1:42 - Quickfire round3:04 - What are fungi?8:40 - The connection between fungi, plants & gut health14:10 - The human impact on fungi19:41 - Mushrooms and mental health 28:01 - Fungi as medicine35:34 - Why should we eat mushrooms40:39 - How to introduce more mushrooms into your diet46:56 - How often should you eat mushrooms51:17 - Summary56:01 - OutroMentioned in today's episode: Potential role of ergothioneine rich mushroom as anti-aging candidate through elimination of neuronal senescent cells from Brain ResearchMedicinal mushrooms in adjuvant cancer therapies: An approach to anticancer effects and presumed mechanisms of action from NutrireImmunomodulatory effect of mushrooms and their bioactive compounds in cancer: A comprehensive review from Biomedicine & Pharmacotherapy Episode transcripts are available here.Is there a nutrition topic you'd like us to explore? Email us at podcast@joinzoe.com, and we'll do our best to cover it.

If you've looked in the mirror lately and you see something that makes you wonder about surgery or botox and that is just not you, but you'd love a natural facelift with no negative side effects, this is for you. First though, I'm a low maintenance girl. I am also a skeptic. Look, I get access to some truly amazing products and I've shared my favorites with you. Today, though I share something that this 59- almost 60yr old face is loving.  I started using this 5-6 weeks ago and have seen (and felt amazing results). I know that we are ALL looking for better products and healthier aging and there is no substitute for the real thing.  My wish is just a clean makeup-free face that I feel good about. I do wear makeup at times but I don't want to have to wear makeup to cover up my face.  I think you'll like this!  My Guest: Cathy Goldstein, an Acupuncture Physician, founded Multiple Integrative Health Clinics. She has been a columnist for New Vision Magazine and Philadelphia Magazine. Guest lecturer at Jefferson University Medical School. She is a frequent speaker for symposiums and health summits. Cathy is considered a subject matter expert in BioMedicine through Eastern Medicine. She has been an educational instructor nationally and internationally. Cathy has been practicing and teaching alternative medicine for more than 34 years (since 1988). She specializes in Quantum Energy Medicine technology and Body-Mind-Neuro-Psychology. She has trained with world-renowned practitioners and healers and holds advanced anatomy, physiology, and skin science studies. Cathy's pursuit of functional health stems from her health challenges and frustrations with Western Medicine. She was diagnosed with Crohn's disease in her 20's. After multiple hospitalizations and complications, she was still suffering from illness. Cathy began her life path for healing. “I am truly grateful for my experience. I refused to have an illness define me. Through determination, relentless studies, and trial and error, I have been fortunate to enjoy a healthy life with no signs of Crohn's disease for over 30 years. My commitment is to help and educate patients and colleagues on alternative healthcare and root functional health.” This natural facelift is going to sound too good to be true, but it is everything you want it to be!  Questions We Answer in This Episode:  What is so different about this product?  Tell us about energy medicine and the liquid nervous system I'm enamored with Power Plate, fell in love with Whole Tones years ago, so explain to listeners how these are related and How can vibrational energy restore the fountain of youth How is Tru Energy different? I know my own feelings about this… and they've surprised even the skeptic in me (and it isn't that I don't want it to work but honestly… that it was this simple.. I love) tell me about other results of raving fans.  How soon do people see results with this 7-minute natural facelift? Do they continue to improve over more time? Connect with Cathy: Try It Yourself! I love this 5-part System! https://www.flippingfifty.com/truenergy Don't just take my word for it, though. Check out this video demo and see for yourself how amazing this product is: On Social: Facebook: https://www.facebook.com/truenergyskincare/ Instagram: https://www.instagram.com/truenergyskincare/ Resources: 7 Minute Natural Facelift: https://www.flippingfifty.com/truenergy Power Plate: https://www.flippingfifty.com/powerplate Whole Tones: https://www.flippingfifty.com/wholetones Other Episodes You Might Like: Your Hormones and Skin in Midlife | Interview with TheSpaDr https://www.flippingfifty.com/hormones-and-skin/ Skincare Tips from the Skin Whisperer https://www.flippingfifty.com/skincare-tips/ How to Redefine Aging | Mindset Shifts with Natalie Jill https://www.flippingfifty.com/redefine-aging/